JY
RCUS icon

Jeff Yass’s Arcus Biosciences RCUS Stock Holding History

Jeff Yass’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.98M Buy
194,000
+135,900
+234% +$3.36M ﹤0.01% 4277
2026
Q1 		$1.25M Buy
58,100
+30,800
+113% +$665K ﹤0.01% 7313
2025
Q4 		$651K Buy
27,300
+9,100
+50% +$186K ﹤0.01% 8204
2025
Q3 		$248K Buy
+18,200
New +$189K ﹤0.01% 10543
2025
Q2 		– Sell
-22,700
Closed -$178K – 13546
2025
Q1 		$178K Sell
22,700
-14,400
-39% -$167K ﹤0.01% 11063
2024
Q4 		$552K Sell
37,100
-6,700
-15% -$109K ﹤0.01% 8426
2024
Q3 		$670K Sell
43,800
-1,500
-3% -$23.7K ﹤0.01% 7777
2024
Q2 		$690K Sell
45,300
-36,200
-44% -$584K ﹤0.01% 7462
2024
Q1 		$1.54M Buy
81,500
+10,400
+15% +$180K ﹤0.01% 5940
2023
Q4 		$1.36M Sell
71,100
-26,500
-27% -$424K ﹤0.01% 6221
2023
Q3 		$1.75M Sell
97,600
-29,800
-23% -$599K ﹤0.01% 5404
2023
Q2 		$2.59M Sell
127,400
-56,400
-31% -$1.07M ﹤0.01% 4634
2023
Q1 		$3.35M Buy
183,800
+53,700
+41% +$1.03M ﹤0.01% 4097
2022
Q4 		$2.69M Buy
130,100
+44,800
+53% +$1.23M ﹤0.01% 4185
2022
Q3 		$2.23M Sell
85,300
-62,300
-42% -$1.65M ﹤0.01% 4691
2022
Q2 		$3.74M Buy
147,600
+46,000
+45% +$1.13M ﹤0.01% 3691
2022
Q1 		$3.21M Buy
101,600
+65,700
+183% +$2.2M ﹤0.01% 4497
2021
Q4 		$1.45M Sell
35,900
-21,300
-37% -$826K ﹤0.01% 6293
2021
Q3 		$2M Sell
57,200
-13,700
-19% -$426K ﹤0.01% 5837
2021
Q2 		$1.95M Buy
70,900
+36,500
+106% +$1.04M ﹤0.01% 5972
2021
Q1 		$966K Buy
34,400
+21,100
+159% +$734K ﹤0.01% 7834
2020
Q4 		$345K Sell
13,300
-62,300
-82% -$1.51M ﹤0.01% 8997
2020
Q3 		$1.3M Buy
75,600
+6,100
+9% +$136K ﹤0.01% 5503
2020
Q2 		$1.72M Buy
+69,500
New +$1.88M ﹤0.01% 4767

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Jeff Yass's RCUS Position: Q2 2026 in Review

Jeff Yass reduced its Arcus Biosciences (RCUS) stake by 95% in Q2 2026, selling an estimated $3.36M and leaving 7,488 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #11650.

Jeff Yass first reported a position in RCUS in Q2 2019 and has held it in 27 quarters since. The position peaked at $8.15M in Q4 2025. 228 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Jeff Yass held 7,488 shares of Arcus Biosciences worth $231K as of Q2 2026.
  • Jeff Yass sold 135,883 Arcus Biosciences shares in Q2 2026, an estimated $3.36M.
  • Arcus Biosciences made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11650 holding.
  • Jeff Yass first reported a position in Arcus Biosciences in Q2 2019 and has held it in 27 quarters since.
  • Jeff Yass's Arcus Biosciences position peaked at $8.15M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.